Robust anti-obesity and metabolic effects of a dual GLP-1/glucagon receptor peptide agonist in rodents and non-human primates.
S J HendersonA KonkarD C HornigoldJames L TrevaskisR JacksonM Fritsch FredinR Jansson-LöfmarkJ NaylorA RossiM A BednarekN BhagrooH SalariS WillS OldhamG HansenM FeighT KleinJ GrimsbyS MaguireL JermutusC M RondinoneM P CoghlanPublished in: Diabetes, obesity & metabolism (2016)
Repeated administration of MEDI0382 elicits profound weight loss in DIO mice and non-human primates, produces robust glucose control and reduces hepatic fat content and fasting insulin and glucose levels. The balance of activities at the GLP-1 and glucagon receptors is considered to be optimal for achieving weight and glucose control in overweight or obese Type 2 diabetic patients.
Keyphrases
- weight loss
- blood glucose
- bariatric surgery
- glycemic control
- endothelial cells
- roux en y gastric bypass
- type diabetes
- weight gain
- gastric bypass
- insulin resistance
- adipose tissue
- metabolic syndrome
- high fat diet induced
- induced pluripotent stem cells
- physical activity
- body mass index
- pluripotent stem cells
- obese patients
- blood pressure
- intellectual disability